{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-23-000567","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.771424+00:00","generated_at":"2026-06-08T11:57:40.716866+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"KORU Medical Q3 revenue down 9.8% YoY; cuts full-year guidance to $28.0-$28.5M","bullets":["Q3 net revenue $7.0M (-9.8% YoY); net loss $1.4M ($0.03/share) vs $1.2M loss prior year.","Full-year 2023 revenue guidance cut to $28.0-$28.5M from $31.0-$32.5M; gross margin reaffirmed 58%-60%.","FDA cleared FREEDOM60 Infusion System for use with Hizentra 50 mL prefilled syringes; first such clearance.","Appointed Ken Miller as CCO effective Nov 6; base salary $360K, bonus up to 50%, and 400,000 stock options."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-23-000567","json":"https://secwatch.observer/filing/0001161697-23-000567.json","markdown":"https://secwatch.observer/filing/0001161697-23-000567.md","text":"https://secwatch.observer/filing/0001161697-23-000567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000567/0001161697-23-000567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000567/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:57:40.716866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a80866789ade7ed41bbc2ce38e2b36a769a182c3","claim":"KORU Medical Systems, Inc. reported third quarter ended September 30, 2023 results: revenue $7.0 million, net income $1.4 million, or $(0.03) per diluted share. Guidance reaffirmed.","evidence_excerpt":"life for patients, today reported financial results for the third quarter ended September 30, 2023 and updates full year 2023 outlook. Highlights: ● Third quarter net revenue of $7.0 million, a 10% decline versus prior year ● Novel Therapies net revenue decline of $0.6 million was impacted primarily by a large clinical trial order in the prior year and timing of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000567/0001161697-23-000567-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$7.0 million"},{"label":"Net income","value":"$1.4 million, or $(0.03) per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e1e0b919d5ab02b820f3cbdba01f17a59225ede3","claim":"KORU Medical Systems, Inc. reported full year 2023 results: revenue $28.0 to $28.5 million. Guidance reaffirmed.","evidence_excerpt":"● Continued strategic, operational expense discipline, ending the quarter with $10.8 million in cash and cash equivalents ● Revised full year 2023 net revenue guidance to $28.0 to $28.5 million, reaffirmed gross margin guidance between 58%-60% for full-year and a planned Q4 exit between 60%-62%, and increased year-end cash balance guidance to greater","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000567/0001161697-23-000567-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$28.0 to $28.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"231603e00e","claim":"Kenneth Miller was appointed as Chief Commercial Officer at KORU Medical Systems, Inc..","evidence_excerpt":"Kenneth Miller, age 55, has been appointed by KORU Medical Systems, Inc. (the “Company”) to serve in the newly created position of Chief Commercial Officer commencing November 6, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000567/0001161697-23-000567-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}